JP2018513188A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513188A5
JP2018513188A5 JP2017555494A JP2017555494A JP2018513188A5 JP 2018513188 A5 JP2018513188 A5 JP 2018513188A5 JP 2017555494 A JP2017555494 A JP 2017555494A JP 2017555494 A JP2017555494 A JP 2017555494A JP 2018513188 A5 JP2018513188 A5 JP 2018513188A5
Authority
JP
Japan
Prior art keywords
compound
meropenem
pharmaceutically acceptable
acceptable salt
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017555494A
Other languages
English (en)
Japanese (ja)
Other versions
JP6945452B2 (ja
JP2018513188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/028437 external-priority patent/WO2016172208A1/en
Publication of JP2018513188A publication Critical patent/JP2018513188A/ja
Publication of JP2018513188A5 publication Critical patent/JP2018513188A5/ja
Priority to JP2021101472A priority Critical patent/JP7245289B2/ja
Application granted granted Critical
Publication of JP6945452B2 publication Critical patent/JP6945452B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017555494A 2015-04-24 2016-04-20 細菌感染症の処置方法 Active JP6945452B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021101472A JP7245289B2 (ja) 2015-04-24 2021-06-18 細菌感染症の処置方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562152668P 2015-04-24 2015-04-24
US62/152,668 2015-04-24
PCT/US2016/028437 WO2016172208A1 (en) 2015-04-24 2016-04-20 Methods of treating bacterial infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021101472A Division JP7245289B2 (ja) 2015-04-24 2021-06-18 細菌感染症の処置方法

Publications (3)

Publication Number Publication Date
JP2018513188A JP2018513188A (ja) 2018-05-24
JP2018513188A5 true JP2018513188A5 (enExample) 2019-05-30
JP6945452B2 JP6945452B2 (ja) 2021-10-06

Family

ID=57144340

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017555494A Active JP6945452B2 (ja) 2015-04-24 2016-04-20 細菌感染症の処置方法
JP2021101472A Active JP7245289B2 (ja) 2015-04-24 2021-06-18 細菌感染症の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021101472A Active JP7245289B2 (ja) 2015-04-24 2021-06-18 細菌感染症の処置方法

Country Status (8)

Country Link
US (2) US20160339045A1 (enExample)
EP (1) EP3285776B1 (enExample)
JP (2) JP6945452B2 (enExample)
CN (2) CN112755039A (enExample)
AU (1) AU2016252555A1 (enExample)
CA (1) CA2982911C (enExample)
ES (1) ES2942329T3 (enExample)
WO (1) WO2016172208A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
JP2016509594A (ja) 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
FI3604316T3 (fi) 2014-05-05 2024-02-29 Melinta Therapeutics Inc Boronaattisuolojen synteesi
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
KR102768209B1 (ko) * 2017-01-09 2025-02-18 멜린타 테라퓨틱스, 엘엘씨 세균 감염을 치료하는 방법
JOP20200075A1 (ar) 2017-10-03 2020-04-30 Melinta Therapeutics Inc طرق لعلاج حالات عدوى بكتيرية
EP3694864B1 (en) 2017-10-11 2025-03-05 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
CN116098993B (zh) * 2022-11-17 2024-10-25 中国农业科学院特产研究所 一种狐、貉肺炎三联灭活疫苗及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof

Similar Documents

Publication Publication Date Title
JP2018513188A5 (enExample)
Douafer et al. Scope and limitations on aerosol drug delivery for the treatment of infectious respiratory diseases
JP2011173928A5 (enExample)
JP2005520778A5 (enExample)
JP6353577B2 (ja) 組み合わせ組成物
JP2019517542A5 (enExample)
JP2018513107A5 (enExample)
JP2019524865A5 (enExample)
JP2016185995A5 (enExample)
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2009529502A5 (enExample)
JP2013541583A5 (enExample)
JP2011503044A5 (enExample)
JP2020510043A5 (enExample)
JP2016505050A5 (enExample)
JP2020515523A5 (enExample)
JP2020504154A5 (enExample)
JP2014148552A5 (enExample)
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
CN107714678B (zh) 紫檀芪在制备mcr-1酶抑制剂中的应用
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物
JP2019535830A5 (enExample)
CN108472375A (zh) 中重度流感的治疗方法
JP2010519274A5 (enExample)
EP1875918B1 (en) New use of ammonium chloride for the therapy of total or partial hepatic failure and necrosis